股本结构
单位：万股
| 公告日期 | 2024-02-09 | 2023-12-15 | 2023-10-10 | 2023-08-09 | 2023-05-11 | 2023-02-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 317.18 | 316.47 | 301.34 | 2109.37 | 2058.77 | 2005.87 |
| 普通股本 | 317.18 | 316.47 | 301.34 | 2109.37 | 2058.77 | 2005.87 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-02-09 | 2023-12-13 | 2023-10-11 | 2023-08-09 | 2023-05-10 | 2023-02-09 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-02-09 | 317.18 | 未披露 | 定期报告 | 2024-02-09 |
| 2023-12-15 | 316.47 | 未披露 | 定期报告 | 2023-12-13 |
| 2023-10-10 | 301.34 | 未披露 |
更多>>
Edesa Biotech, Inc. announcing that it intends to effect a one-for-seven reverse share split of its common shares.
|
2023-10-11 |
| 2023-08-09 | 2109.37 | 未披露 | 定期报告 | 2023-08-09 |
| 2023-05-11 | 2058.77 | 未披露 | 定期报告 | 2023-05-10 |
| 2023-02-10 | 2005.87 | 未披露 | 定期报告 | 2023-02-09 |
| 2023-02-10 | 1935.34 | 未披露 |
更多>>
From September 30, 2022 to December 31, 2022
Issuance of common shares and warrants in equity offering
|
2022-12-31 |
| 2022-12-23 | 1935.34 | 未披露 | 定期报告 | 2022-12-14 |
| 2022-12-16 | 1666.20 | 未披露 |
更多>>
From September 30, 2021 to September 30, 2022
Issuance of common shares and warrants in equity offering
Issuance of common shares upon exercise of pre-funded warrants, net of costs
|
2022-09-30 |
| 2022-05-13 | 1546.23 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common shares and warrants in equity offering
|
2022-03-31 |
| 2022-03-24 | 1666.20 | 未披露 |
更多>>
1.Common Shares by 1,540,000 Common Shares.
2.The number of Common Shares to be outstanding after the offering is based on 13,922,287 of Common Shares outstanding as of March 21, 2022.
|
2022-03-24 |
| 2022-03-23 | 1392.23 | 未披露 | 定期报告 | 2022-03-21 |
| 2022-02-14 | 1377.53 | 未披露 | 定期报告 | 2022-02-11 |
| 2022-02-14 | 1351.88 | 未披露 |
更多>>
From September 30, 2021 to December 31, 2021
Issuance of common shares in equity offerings
|
2021-12-31 |
| 2021-12-28 | 1329.54 | 未披露 |
更多>>
From September 30, 2020 to September 30, 2021
Issuance of common shares in equity offerings
Issuance costs including fair value of underwriter warrants
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of share options
Conversion of convertible preferred shares
|
2021-09-30 |
| 2021-05-14 | 1325.56 | 未披露 | 定期报告 | 2021-05-13 |
| 2021-05-14 | 1324.66 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Issuance of common shares in equity offerings
Issuance costs including fair value of underwriter warrants
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of share options
Conversion of convertible preferred shares
|
2021-03-31 |
| 2021-03-03 | 1317.84 | 未披露 |
更多>>
1.Securities offered by the company pursuant to this prospectus supplement: 1,562,500 Common Shares.
2.The number of Common Shares to be outstanding after the offering is based on 11,615,942 of Common Shares outstanding as of February 23, 2021.
|
2021-03-01 |
| 2021-02-25 | 1161.59 | 未披露 | 定期报告 | 2021-02-23 |
| 2021-02-16 | 1104.90 | 未披露 | 定期报告 | 2021-02-11 |
| 2020-12-07 | 1052.31 | 未披露 |
更多>>
From September 30, 2020 to December 2,2020
Issuance of common shares in equity offering
Issuance of common shares upon exercise of warrants
Issuance of common shares upon conversion of preferred shares
|
2020-12-02 |
| 2020-12-07 | 961.51 | 未披露 |
更多>>
From September 30, 2019 to September 30, 2020
Issuance of common shares in equity offering
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of share options
Issuance costs
|
2020-09-30 |
| 2020-09-28 | 960.89 | 未披露 | 定期报告 | 2020-09-24 |
| 2020-08-12 | 941.43 | 未披露 | 定期报告 | 2020-08-10 |
| 2020-08-12 | 886.19 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common shares upon exercise of warrants
|
2020-06-30 |
| 2020-05-15 | 885.92 | 未披露 |
更多>>
From December 31, 2019 to February 13, 2020
Issuance of common shares and warrants in equity offering
Issuance costs
|
2020-02-13 |
| 2020-01-08 | 885.98 | 未披露 | 定期报告 | 2020-01-08 |
| 2019-08-14 | 750.45 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Preferred return for Class A preferred shares
Effect of reverse acquisition
|
2019-06-30 |
| 2019-06-10 | 713.82 | 未披露 |
更多>>
In connection with the closing of the transaction, the combined company plans to effect a one-for-six reverse share split at 4:00 p.m. Eastern Time on June 7, 2019. At the effective time of the reverse share split, every six shares of the combined company’s common shares will be consolidated into one common share. No fractional shares will be issued in the reverse share split. Following the closing of the exchange transaction and after giving effect to the reverse share split, the combined company expects to have approximately 7,138,233, shares issued and outstanding.
|
2019-06-10 |
| 2018-11-30 | 533.07 | 未披露 |
更多>>
From September 30, 2017 to June 30, 2018
Issuance of common shares in equity offering
Issuance costs including fair value of placement agent warrants
Issuance of common shares upon exercise of warrants
|
2018-06-30 |
| 2018-06-06 | 511.85 | 未披露 | 定期报告 | 2018-06-01 |
| 2018-05-08 | 150.29 | 未披露 |
更多>>
Stellar Biotechnologies, Inc.is announcing a one-for-seven reverse share split of its common shares. The company anticipates that the reverse share split will become effective at 4:00 p.m. Eastern Time on May 4, 2018, and the company's common shares will trade on a post-split basis under the company's existing trading symbol "SBOT," at the market open on May 7, 2018.
|
2018-05-07 |
| 2017-12-01 | 1052.01 | 未披露 |
更多>>
From September 30, 2016 To June 30, 2017
Issuance of performance shares
|
2017-06-30 |
| 2016-12-14 | 1013.63 | 未披露 |
更多>>
from September 30, 2015 to August 5, 2016
Issuance of common shares
Proceeds from exercise of warrants
|
2016-08-05 |
| 2016-02-08 | 844.88 | 未披露 | 定期报告 | 2015-12-31 |
| 2015-12-14 | 842.48 | 未披露 | 定期报告 | 2015-12-01 |
| 2015-12-14 | 798.48 | 未披露 |
更多>>
from September 30, 2014 to September 30, 2015
Proceeds from exercise of warrants
Proceeds from exercise of options
On September 2, 2015, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10.
|
2015-09-30 |
| 2015-08-10 | 7954.67 | 未披露 | 定期报告 | 2015-06-30 |
Edesa Biotech, Inc. announcing that it intends to effect a one-for-seven reverse share split of its common shares.
From September 30, 2022 to December 31, 2022
Issuance of common shares and warrants in equity offering
From September 30, 2021 to September 30, 2022
Issuance of common shares and warrants in equity offering
Issuance of common shares upon exercise of pre-funded warrants, net of costs
From December 31, 2021 to March 31, 2022
Issuance of common shares and warrants in equity offering
1.Common Shares by 1,540,000 Common Shares.
2.The number of Common Shares to be outstanding after the offering is based on 13,922,287 of Common Shares outstanding as of March 21, 2022.
From September 30, 2021 to December 31, 2021
Issuance of common shares in equity offerings
From September 30, 2020 to September 30, 2021
Issuance of common shares in equity offerings
Issuance costs including fair value of underwriter warrants
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of share options
Conversion of convertible preferred shares
From December 31, 2020 To March 31, 2021
Issuance of common shares in equity offerings
Issuance costs including fair value of underwriter warrants
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of share options
Conversion of convertible preferred shares
1.Securities offered by the company pursuant to this prospectus supplement: 1,562,500 Common Shares.
2.The number of Common Shares to be outstanding after the offering is based on 11,615,942 of Common Shares outstanding as of February 23, 2021.
From September 30, 2020 to December 2,2020
Issuance of common shares in equity offering
Issuance of common shares upon exercise of warrants
Issuance of common shares upon conversion of preferred shares
From September 30, 2019 to September 30, 2020
Issuance of common shares in equity offering
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of share options
Issuance costs
From March 31, 2020 to June 30, 2020
Issuance of common shares upon exercise of warrants
From December 31, 2019 to February 13, 2020
Issuance of common shares and warrants in equity offering
Issuance costs
From March 31, 2019 to June 30, 2019
Preferred return for Class A preferred shares
Effect of reverse acquisition
In connection with the closing of the transaction, the combined company plans to effect a one-for-six reverse share split at 4:00 p.m. Eastern Time on June 7, 2019. At the effective time of the reverse share split, every six shares of the combined company’s common shares will be consolidated into one common share. No fractional shares will be issued in the reverse share split. Following the closing of the exchange transaction and after giving effect to the reverse share split, the combined company expects to have approximately 7,138,233, shares issued and outstanding.
From September 30, 2017 to June 30, 2018
Issuance of common shares in equity offering
Issuance costs including fair value of placement agent warrants
Issuance of common shares upon exercise of warrants
Stellar Biotechnologies, Inc.is announcing a one-for-seven reverse share split of its common shares. The company anticipates that the reverse share split will become effective at 4:00 p.m. Eastern Time on May 4, 2018, and the company's common shares will trade on a post-split basis under the company's existing trading symbol "SBOT," at the market open on May 7, 2018.
From September 30, 2016 To June 30, 2017
Issuance of performance shares
from September 30, 2015 to August 5, 2016
Issuance of common shares
Proceeds from exercise of warrants
from September 30, 2014 to September 30, 2015
Proceeds from exercise of warrants
Proceeds from exercise of options
On September 2, 2015, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10.